


PRODUCT INFORMATION



RO3244794
Item No. 25350

CAS Registry No.: 361457-01-4
Formal Name: 4-fluoro-N-[[[5-(4-fluorophenyl)-2-benzofuranyl]methoxy]carbonyl]-D-phenylalanine
MF: C₂₅H₁₉F₂NO₅
FW: 451.4
Purity: ≥98%
Supplied as: A solid
Storage: -20°C
Stability: ≥4 years



Information represents the product specifications. Batch specific analytical results are provided on each certificate of analysis.

Laboratory Procedures

RO3244794 is supplied as a solid. A stock solution may be made by dissolving the RO3244794 in the solvent of choice, which should be purged with an inert gas. RO3244794 is soluble (≥10 mg/ml) in DMSO. RO3244794 is sparingly soluble (1-10 mg/ml) in ethanol.

Description

RO3244794 is an IP receptor antagonist ($K_i = 20$ nM in isolated human platelets).¹ It is selective for the IP receptor over a panel of 50 receptors at 10 μ M but does bind to the prostaglandin E₂ (PGE₂) receptor subtypes EP₃ and EP₄, TP receptor, and adenosine A₃ receptor (K_i s = 4,169, 1,820, 8,128, and 4,786 nM, respectively). RO3244794 inhibits cAMP accumulation induced by carbaprostacyclin (Item No. 18210) in CHO-K1 cells expressing the human IP receptor ($IC_{50} = 316$ nM). It prevents treprostiniol-induced relaxation in U-46619-precontracted isolated rat pulmonary arteries when used at a concentration of 1 μ M.² RO3244794 (250 nM) inhibits PGI₂- or 12-HETrE-induced aggregation of isolated human platelet-rich plasma.³ It decreases acetic-acid induced writhing and carrageenan-induced mechanical hyperalgesia and edema in rats.¹ RO3244794 (10 mg/kg) also decreases the difference in weight distribution between the osteoarthritic and control hind paws in a rat model of sodium monoiodoacetate-induced osteoarthritis.

References

1. Bley, K.R., Bhattacharya, A., Daniels, D.V., *et al.* RO1138452 and RO3244794: Characterization of structurally distinct, potent and selective IP (prostacyclin) receptor antagonists. *Br. J. Pharmacol.* **147**(3), 335-345 (2006).
2. Orié, N.N., Ledwozyw, A., Williams, D.J., *et al.* Differential actions of the prostacyclin analogues treprostiniol and iloprost and the selexipag metabolite, MRE-269 (ACT-333679) in rat small pulmonary arteries and veins. *Prostaglandins Other Lipid Mediat.* **106**, 1-7 (2013).
3. Tourdot, B.E., Adili, R., Isingizwe, Z.R., *et al.* 12-HETrE inhibits platelet reactivity and thrombosis in part through the prostacyclin receptor. *Blood Adv.* **1**(15), 1124-1131 (2017).

WARNING

THIS PRODUCT IS FOR RESEARCH ONLY - NOT FOR HUMAN OR VETERINARY DIAGNOSTIC OR THERAPEUTIC USE.

SAFETY DATA

This material should be considered hazardous until further information becomes available. Do not ingest, inhale, get in eyes, on skin, or on clothing. Wash thoroughly after handling. Before use, the user must review the [complete](#) Safety Data Sheet, which has been sent via email to your institution.

WARRANTY AND LIMITATION OF REMEDY

Buyer agrees to purchase the material subject to Cayman's Terms and Conditions. Complete Terms and Conditions including Warranty and Limitation of Liability information can be found on our website.

Copyright Cayman Chemical Company, 02/05/2026

CAYMAN CHEMICAL

1180 EAST ELLSWORTH RD
ANN ARBOR, MI 48108 · USA

PHONE: [800] 364-9897
[734] 971-3335

FAX: [734] 971-3640

CUSTSERV@CAYMANCHEM.COM
WWW.CAYMANCHEM.COM